WHAT IS DELSTRIGO?
+

DELSTRIGO is a complete, one-pill prescription HIV medicine used to treat HIV-1 infection in adults who have not received HIV-1 medicines in the past, or to replace their current HIV-1 medicines for people whose healthcare provider determines that they meet certain requirements. HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

 

You May Be Able to Lower Your HIV Viral Load to Undetectable

ABOUT DELSTRIGO

WHAT IT DOES

DELSTRIGO may help lower your viral load to undetectable.

In a study of adults who were new to HIV-1 treatment, the percentage of those who had an undetectable viral load at week 96 were:

77% when taking DELSTRIGO

VS

74% when taking Atripla
(another HIV-1 medicine)

DELSTRIGO may not have these effects in all patients.

DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) May Help Lower Your Viral Load to UndetectableIn a 48-Week Study of Adults Who Were New to HIV-1 Treatment, the Percentage of Those Who Reached an Undetectable Viral Load was 84% When Taking DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate)DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) May Help Lower Your Viral Load to UndetectableIn a 48-Week Study of Adults Who Were New to HIV-1 Treatment, the Percentage of Those Who Reached an Undetectable Viral Load was 84% When Taking DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate)
The Safety and Efficacy of DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) was Compared to Atripla Over 48 Weeks in Adults Who Were New to HIV-1 Treatment The Safety and Efficacy of DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) was Compared to Atripla Over 48 Weeks in Adults Who Were New to HIV-1 Treatment

HOW IT WAS STUDIED

The safety and efficacy of DELSTRIGO was compared to Atripla over 96 weeks in adults who were new to HIV-1 treatment.

364 adults took DELSTRIGO

364 adults took Atripla

Patients were assigned by chance to take one of the two treatment regimens, and neither the patient nor the healthcare providers taking part in the study knew which regimen they were taking.


 

 
TRUSTe Verified Privacy TRUSTe APEC Privacy

Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

For United States, its territories, and Puerto Rico only. US-DOR-00693 09/20

Worsening of hepatitis B virus infection (HBV). If you have both Human Immunodeficiency Virus-1 (HIV-1) and HBV and stop taking DELSTRIGO, your HBV may suddenly get worse. Do not stop taking DELSTRIGO without first talking to your doctor, as they will need to monitor your health. Your doctor should test you for HBV infection before you start treatment with DELSTRIGO.